» Articles » PMID: 20370893

Prolyl Oligopeptidase is Inhibited in Relapsing-remitting Multiple Sclerosis

Overview
Publisher Biomed Central
Date 2010 Apr 8
PMID 20370893
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Multiple sclerosis (MS) is a complex, inflammatory and neurodegenerative disease of the central nervous system leading to long-term disability. Recent studies indicate a close association between inflammation and neurodegeneration in all lesions and disease stages of MS. Prolyl oligopeptidase (POP) is a proline-specific serine protease that cleaves several neuroactive peptides. This peptidase has been implicated in neurodegeneration, as well as in the modulation of the inflammatory response.

Methods: We examined plasma POP and the levels of an endogenous POP inhibitor from relapsing remitting MS patients and compared these with healthy controls, by monitoring the fluorescent changes due to standard fluorescently labelled substrate cleavage. We analysed the data in relationship to patient age and disease disability status.

Results: We observed a significant decrease in POP activity in plasma of relapsing remitting MS patients relative to healthy controls, coupled with an increase of POP endogenous inhibitor. The POP activity was also correlated with patient age and disability status. The lowered POP activity from plasma of MS patients could be rescued by reductants

Conclusions: The decrease in circulating POP activity measured in MS is reverted by reductants. This suggests that POP inactivation in MS might be a result of the oxidative conditions prevailing in the plasma of the diseased patients. Plasma levels of POP activity as well as those of their endogenous inhibitor are suggested as biomarkers of inflammation and oxidative stress in MS.

Citing Articles

Abnormal Expression of Prolyl Oligopeptidase (POP) and Its Catalytic Products Ac-SDKP Contributes to the Ovarian Fibrosis Change in Polycystic Ovary Syndrome (PCOS) Mice.

Han S, Wang S, Fan X, Chen M, Wang X, Huang Y Biomedicines. 2023; 11(7).

PMID: 37509566 PMC: 10377061. DOI: 10.3390/biomedicines11071927.


The Prolyl Oligopeptidase Inhibitor KYP-2047 Is Cytoprotective and Anti-Inflammatory in Human Retinal Pigment Epithelial Cells with Defective Proteasomal Clearance.

Toppila M, Hytti M, Korhonen E, Ranta-Aho S, Harju N, Forsberg M Antioxidants (Basel). 2023; 12(6).

PMID: 37372009 PMC: 10295660. DOI: 10.3390/antiox12061279.


Post-Proline Cleaving Enzymes (PPCEs): Classification, Structure, Molecular Properties, and Applications.

Baharin A, Ting T, Goh H Plants (Basel). 2022; 11(10).

PMID: 35631755 PMC: 9147577. DOI: 10.3390/plants11101330.


The Inhibition of Prolyl Oligopeptidase as New Target to Counteract Chronic Venous Insufficiency: Findings in a Mouse Model.

Casili G, Lanza M, Scuderi S, Messina S, Paterniti I, Campolo M Biomedicines. 2020; 8(12).

PMID: 33322134 PMC: 7764674. DOI: 10.3390/biomedicines8120604.


N-acetyl-seryl-aspartyl-lysyl-proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects.

Kanasaki K J Diabetes Investig. 2020; 11(3):516-526.

PMID: 31997585 PMC: 7232267. DOI: 10.1111/jdi.13219.


References
1.
Brandt I, Gerard M, Sergeant K, Devreese B, Baekelandt V, Augustyns K . Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein. Peptides. 2008; 29(9):1472-8. DOI: 10.1016/j.peptides.2008.05.005. View

2.
Maes M, Lin A, Bonaccorso S, Goossens F, Van Gastel A, Pioli R . Higher serum prolyl endopeptidase activity in patients with post-traumatic stress disorder. J Affect Disord. 1999; 53(1):27-34. DOI: 10.1016/s0165-0327(98)00086-x. View

3.
Salers P . Evidence for the presence of prolyl oligopeptidase and its endogenous inhibitor in neonatal rat pancreatic beta-cells. Regul Pept. 1994; 50(3):235-45. DOI: 10.1016/0167-0115(94)90004-3. View

4.
Maes M, Libbrecht I, van Hunsel F, Lin A, Bonaccorso S, Goossens F . Lower serum activity of prolyl endopeptidase in fibromyalgia is related to severity of depressive symptoms and pressure hyperalgesia. Psychol Med. 1998; 28(4):957-65. DOI: 10.1017/s0033291798006801. View

5.
Kurtzke J . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11):1444-52. DOI: 10.1212/wnl.33.11.1444. View